Chronic Pancreatitis — RepurpOS

Disease overview

Alterations

134

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

183

Natural agents

Natural products

Merged ranked

215

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, Examine.com · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Progressive exocrine and endocrine insufficiency; spontaneous improvement possible in alcoholic CP with sustained abstinence (30-40% pain improvement); structural damage (fibrosis, calcifications) is irreversible

Best-intervention remission

Abstinence from alcohol in alcoholic CP: 30-40% pain improvement; endoscopic drainage of ductal obstruction: pain relief in 65-70% at 5 years; total pancreatectomy with islet autotransplantation (TPIAT): 85-90% narcotic independence at 3 years in refractory cases; antioxidant therapy: modest evidence

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — endoscopic therapy and surgery are underused in eligible patients; most are managed with analgesics indefinitely

Primary barrier

practice/access

Barrier detail: Pain management in CP often escalates to opioids without adequate trial of endoscopic decompression or TPIAT in eligible patients; TPIAT (total pancreatectomy + islet autotransplantation) for refractory pain is highly effective but available at only ~20 centres in the US; delayed referral is the dominant gap

Last SoC change: 2018 — AGA/ACG chronic pancreatitis guidelines updated; endoscopic therapy (ESWL + endoscopy) vs surgery (ESCAPE trial 2020) — surgery superior at 5 years for painful CP with duct dilatation; no major pharmacotherapy change in decades

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005003 · ORPHA: ORPHA:676

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Chronic Pancreatitis may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 3, Phase 2: 15, Phase 1: 10

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

134

Actionable

Pipeline Compounds (Top 6)

Bupivacaine, Pancrelipase, Triamcinolone, Bupropion, Cannabinol, Diazepam

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 134 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abdominal pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal circulating enzyme concentration or activity	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Abnormal pancreatic duct morphology	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormal thrombosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chronic calcifying pancreatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chronic pancreatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Diabetes mellitus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Elevated circulating C-reactive protein concentration	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Epigastric pain	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Exocrine pancreatic insufficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Fever	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Increased total leukocyte count	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Insulin-dependent but ketosis-resistant diabetes	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO LOINC
Jaundice	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Malnutrition	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nausea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Neoplasm of the pancreas	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pancreatic adenocarcinoma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pancreatic calcification	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pancreatic pseudocyst	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pancreatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pleural effusion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Recurrent pancreatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Splanchnic vein thrombosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Steatorrhea	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Vomiting	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Weight loss	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
AADACL3 arylacetamide deacetylase like 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AIRE autoimmune regulator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALDH2 aldehyde dehydrogenase 2 family member	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATF7 activating transcription factor 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCL2A1 BCL2 related protein A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRAF B-Raf proto-oncogene, serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRAP BRCA1 associated protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1A calcium voltage-gated channel subunit alpha1 A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1B calcium voltage-gated channel subunit alpha1 B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1C calcium voltage-gated channel subunit alpha1 C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1D calcium voltage-gated channel subunit alpha1 D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1E calcium voltage-gated channel subunit alpha1 E	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1F calcium voltage-gated channel subunit alpha1 F	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1G calcium voltage-gated channel subunit alpha1 G	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1H calcium voltage-gated channel subunit alpha1 H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1I calcium voltage-gated channel subunit alpha1 I	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1S calcium voltage-gated channel subunit alpha1 S	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA2D1 calcium voltage-gated channel auxiliary subunit alpha2delta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA2D2 calcium voltage-gated channel auxiliary subunit alpha2delta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA2D3 calcium voltage-gated channel auxiliary subunit alpha2delta 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA2D4 calcium voltage-gated channel auxiliary subunit alpha2delta 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNB1 calcium voltage-gated channel auxiliary subunit beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNB2 calcium voltage-gated channel auxiliary subunit beta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNB3 calcium voltage-gated channel auxiliary subunit beta 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNB4 calcium voltage-gated channel auxiliary subunit beta 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG1 calcium voltage-gated channel auxiliary subunit gamma 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG2 calcium voltage-gated channel auxiliary subunit gamma 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG3 calcium voltage-gated channel auxiliary subunit gamma 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG4 calcium voltage-gated channel auxiliary subunit gamma 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG5 calcium voltage-gated channel auxiliary subunit gamma 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG6 calcium voltage-gated channel auxiliary subunit gamma 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG7 calcium voltage-gated channel auxiliary subunit gamma 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNG8 calcium voltage-gated channel auxiliary subunit gamma 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN2A cyclin dependent kinase inhibitor 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CEL carboxyl ester lipase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CELA2A chymotrypsin like elastase 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CELA3B chymotrypsin like elastase 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CFTR CF transmembrane conductance regulator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CNR1 cannabinoid receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COL4A1 collagen type IV alpha 1 chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COL4A2 collagen type IV alpha 2 chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CPA1 carboxypeptidase A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTRC chymotrypsin C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTSB cathepsin B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change in quality of life (EORTC-QLQ C 30)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
DCC DCC netrin 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DDIT3 DNA damage inducible transcript 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EPAS1 endothelial PAS domain protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ETV3 ETS variant transcription factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FKBP3 FKBP prolyl isomerase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNAS GNAS complex locus	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPAT3 glycerol-3-phosphate acyltransferase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HbA1c (mmol/L)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	LOINC

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ABEMACICLIB		Gene-targeted
ACETALDEHYDE		Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
AFATINIB		Gene-targeted
ALECTINIB		Gene-targeted
ALPELISIB		Gene-targeted
AMLODIPINE BENZOATE	blocker	Gene-targeted
AMLODIPINE BESYLATE	blocker	Gene-targeted
AMLODIPINE BESYLATE		Gene-targeted
AMLODIPINE MALEATE	blocker	Gene-targeted
AMPHETAMINE	None	Gene-targeted
ATENOLOL		Gene-targeted
ATEZOLIZUMAB		Gene-targeted
AXITINIB		Gene-targeted
BEPRIDIL		Gene-targeted
BEPRIDIL HYDROCHLORIDE	blocker	Gene-targeted
BEVACIZUMAB		Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BINIMETINIB		Gene-targeted
BOSUTINIB		Gene-targeted
CAPECITABINE		Gene-targeted
CAPMATINIB		Gene-targeted
CARBACHOL	None	Gene-targeted
CELECOXIB		Gene-targeted
CETUXIMAB		Gene-targeted
CHLOROQUINE		Gene-targeted
CINNARIZINE	blocker	Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CISPLATIN		Gene-targeted
CITALOPRAM		Gene-targeted
CLEVIDIPINE	blocker	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
COBIMETINIB		Gene-targeted
CRIZOTINIB		Gene-targeted
DABRAFENIB	inhibitor; inhibitor	Gene-targeted
DABRAFENIB MESYLATE	inhibitor	Gene-targeted
DASATINIB ANHYDROUS	inhibitor	Gene-targeted
DEHYDRATED ALCOHOL		Gene-targeted
DENOSUMAB		Gene-targeted
DIAZEPAM	None	Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
DIAZEPAM	Small molecule	Approved	Strong	100	5 trials 1 RCT View evidence Registry trials NCT05326542 — Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP (UNKNOWN) NA NCT05270434 — Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis. (COMPLETED) NA NCT05261997 — Endotherapy for Painless Chronic Pancreatitis (UNKNOWN) NA NCT05289362 — Comparison of Efficacy of Basket and Balloon in the Removal of Pancreatic Duct Stones in Chronic Pancreatitis Under ERCP (COMPLETED) NA NCT01318369 — Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
INDOMETHACIN	Small molecule	Approved	Strong	100	4 trials 1 Cochrane 2 Trial pubs 2 RCT View evidence Registry trials NCT04207060 — Trial of Indomethacin in Chronic Pancreatitis (COMPLETED) PHASE1, PHASE2 NCT07202559 — Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy (RECRUITING) NA NCT02797067 — Rectal Indomethacin to Prevent Post ESWL-pancreatitis (COMPLETED) PHASE4 NCT03609944 — SpHincterotomy for Acute Recurrent Pancreatitis (COMPLETED) NA Published literature Cochrane review Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment (World journal of gastroenterology, 2019) Clinical trial publication Oral Indomethacin for Chronic Pancreatitis: Results From the PAIR Randomized Placebo-Controlled Trial (Clinical and translational gastroenterology, 2025) Clinical trial publication Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial (Trials, 2017) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ABEMACICLIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETALDEHYDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AFATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALPELISIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BENZOATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ATENOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEPRIDIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEPRIDIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
BEVACIZUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CETUXIMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CINNARIZINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CITALOPRAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLEVIDIPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEHYDRATED ALCOHOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DENOSUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DILTIAZEM HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DILTIAZEM MALATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOCETAXEL ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXORUBICIN LIPOSOME Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DRONEDARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
BUPIVACAINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PANCRELIPASE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BUPROPION	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CANNABINOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIAZEPAM	Small molecule	Phase II	Emerging	60	5 trials 1 RCT View evidence Registry trials NCT05326542 — Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP (UNKNOWN) NA NCT05270434 — Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis. (COMPLETED) NA NCT05261997 — Endotherapy for Painless Chronic Pancreatitis (UNKNOWN) NA NCT05289362 — Comparison of Efficacy of Basket and Balloon in the Removal of Pancreatic Duct Stones in Chronic Pancreatitis Under ERCP (COMPLETED) NA NCT01318369 — Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FASINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOBUPIVACAINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIDOCAINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREGABALIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOCILIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VARENICLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAMOSTAT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESOMEPRAZOLE MAGNESIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INDOMETHACIN	Small molecule	Phase I	Emerging	35	4 trials 1 Cochrane 2 Trial pubs 2 RCT View evidence Registry trials NCT04207060 — Trial of Indomethacin in Chronic Pancreatitis (COMPLETED) PHASE1, PHASE2 NCT07202559 — Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy (RECRUITING) NA NCT02797067 — Rectal Indomethacin to Prevent Post ESWL-pancreatitis (COMPLETED) PHASE4 NCT03609944 — SpHincterotomy for Acute Recurrent Pancreatitis (COMPLETED) NA Published literature Cochrane review Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment (World journal of gastroenterology, 2019) Clinical trial publication Oral Indomethacin for Chronic Pancreatitis: Results From the PAIR Randomized Placebo-Controlled Trial (Clinical and translational gastroenterology, 2025) Clinical trial publication Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial (Trials, 2017) CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
LACOSAMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PANCREATIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PARICALCITOL	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PROGLUMIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SECRETIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SIMVASTATIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ACARBOSE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ALCOHOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLIMEPIRIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ABEMACICLIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETALDEHYDE Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AFATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALECTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
ALPELISIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BENZOATE Repurposing via CACNA1F	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
AMLODIPINE BESYLATE Repurposing via CACNA1F	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLODIPINE BESYLATE Repurposing via CACNA1C	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE MALEATE Repurposing via CACNA1F	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ATENOLOL Repurposing via CACNA1C	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BEPRIDIL Repurposing via CACNA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
BEPRIDIL HYDROCHLORIDE Repurposing via CACNA1G	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
BEVACIZUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BINIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPMATINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CELECOXIB Repurposing via CACNA1G	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CETUXIMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLOROQUINE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CINNARIZINE Repurposing via CACNA1F	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CIPROFLOXACIN Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	DGIdb	—
CITALOPRAM Repurposing via CACNA1C	Small molecule	Approved	Strong	95	—	DGIdb	—
CLEVIDIPINE Repurposing via CACNA1F	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
COBIMETINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
CRIZOTINIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DABRAFENIB MESYLATE Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DEHYDRATED ALCOHOL Repurposing via ALDH2	Small molecule	Approved	Strong	95	—	DGIdb	—
DENOSUMAB Repurposing via BRAF	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing via ALDH2	Small molecule	Approved	Strong	95	5 trials 1 RCT View evidence Registry trials NCT05326542 — Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP (UNKNOWN) NA NCT05270434 — Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis. (COMPLETED) NA NCT05261997 — Endotherapy for Painless Chronic Pancreatitis (UNKNOWN) NA NCT05289362 — Comparison of Efficacy of Basket and Balloon in the Removal of Pancreatic Duct Stones in Chronic Pancreatitis Under ERCP (COMPLETED) NA NCT01318369 — Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets

Natural Products

9 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Trials & literature	Links
Red Sage Natural product	Nutraceutical	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Cannabinoids Natural product Human Study These results reveal an immunosuppressive effect of cannabinoid prepara…	Nutraceutical	Phase II	Emerging	2 trials View evidence Registry trials NCT01551511 — Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain (COMPLETED) PHASE2 NCT01318369 — Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	—
Chaga Mushroom (Inonotus Obliquus) Natural product Animal Study Inonotus obliquus polysaccharide has strong activity for ameliorating c…	Nutraceutical	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Olive Leaf Extract Natural product Animal Study Olive leaf extract protect against L-arginine induced chronic pancreati…	Nutraceutical	Preclinical	Emerging	1 pubs View evidence CT.gov search · Cochrane · PubMed	—
Flavonoids Natural product Animal Study Psidium guajava flavonoids prevent NLRP3 inflammasome activation and al…	Nutraceutical	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Pterostilbene Natural product Animal Study Pterostilbene can alleviate severe acute pancreatitis-induced tissue da…	Nutraceutical	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Puerarin Natural product Animal Study, In Vitro Study Puerarin could be a potential therapeutic candidate in the treatment of…	Nutraceutical	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Apigenin Natural product Animal Study, In Vitro Study These in vivo and in vitro studies provide novel insights regarding api…	Food compound	Preclinical	Emerging	No indexed hits View evidence CT.gov search · Cochrane · PubMed	PubChem
Neem Natural product In Vitro Study Nimbolide abrogates cerulein-induced chronic pancreatitis.	Nutraceutical	Preclinical	Emerging	1 pubs View evidence CT.gov search · Cochrane · PubMed	—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.